-
Sun Pharma to Invest Rs 240 Crore in Halol Plant for New Products
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced that it will invest Rs 240 crore to expand its Halol manufacturing facility in Gujarat. The expansion project will be used to manufacture new products and increase production capacity.
-
Sun Pharma's Ranbaxy Arm to Acquire US Generics Drugmaker Concert Pharmaceuticals for $576 Million
Sun Pharmaceutical Industries Ltd.'s subsidiary, Ranbaxy Laboratories Ltd., has entered into an agreement to acquire Concert Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, for approximately $576 million in cash.
-
Sun Pharma Q3 Net Profit Rises 8.3% to Rs 2,341 Crore
Sun Pharmaceutical Industries Ltd. (Sun Pharma) on Thursday reported a consolidated net profit of Rs 2,341.22 crore for the third quarter ended December 2022, a growth of 8.3 per cent compared to Rs 2,161.87 crore in the same period last year.
-
Sun Pharma receives USFDA nod for generic Nexavar
The drug is used for treating advanced liver cancer and advanced kidney cancer. The generic version of Nexavar is...
-
Sun Pharma Q3 net profit rises 36%
Sun Pharmaceutical Industries Ltd on Friday reported a 36% year-on-year rise in its consolidated net profit to Rs...
-
Sun Pharma gets USFDA nod for generic cancer drug
Sun Pharmaceutical Industries on Tuesday said it has received final approval from the US health regulator for its...
-
Sun Pharma Receives US FDA Approval for Generic Version of VESIcare Tablets
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has received final approval from the United States Food and Drug Administration (US FDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, the generic version of VESIcare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc.
-
Sun Pharma Launches Biosimilar Pegfilgrastim in Japan
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced the launch of its biosimilar Pegfilgrastim, under the brand name Pelgrapro, in Japan. Pelgrapro is a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor (G-CSF) used to prevent neutropenia in patients undergoing chemotherapy.
-
Sun Pharma's Ilumya Approved in the EU for Treatment of Plaque Psoriasis
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced that the European Commission has granted marketing authorization for Ilumya (tildrakizumab) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.